Table 2.
Types and doses of beta-blockers at baseline in the substudy population (included set) vs. the population of the main SHIFT study6 (randomized set)
| SHIFT echocardiography substudy |
Main study (n = 6505) | |||
|---|---|---|---|---|
| Ivabradine (n = 304) | Placebo (n = 307) | All (n = 611) | ||
| β-blockers | 281 (92%) | 281 (91.5%) | 562 (92%) | 5820 (90%) |
| Carvedilol | 160 (57%) | 149 (53%) | 309 (55%) | 2604 (45%) |
| Bisoprolol | 46 (16%) | 60 (21%) | 106 (19%) | 1486 (26%) |
| Metoprolol succinate | 48 (17%) | 45 (16%) | 93 (17%) | 815 (14%) |
| Metoprolol tartrate | 16 (6%) | 19 (7%) | 35 (6%) | 618 (11%) |
| Nebivolol | 9 (3%) | 9 (3%) | 18 (3%) | 198 (3%) |
| Other | 2 (0.7%) | – | 2 (0.4%) | 107 (1.8%) |
| Mean daily dosage of β-blocker (mg) | ||||
| Carvedilol | 23.5 ± 16.0 | 23.5 ± 17.1 | 23.5 ± 16.5 | 25.0 ± 17.8 |
| Bisoprolol | 6.2 ± 3.2 | 5.7 ± 3.2 | 5.9 ± 3.2 | 6.2 ± 3.3 |
| Metoprolol succinate | 131.3 ± 80.2 | 131.9 ± 73.3 | 131.6 ± 76.5 | 89.9 ± 60.0 |
| Metoprolol tartrate | 72.7 ± 46.2 | 115.8 ± 50.8 | 96.1 ± 52.8 | 69.1 ± 47.4 |
| Nebivolol | 6.4 ± 2.8 | 4.3 ± 2.6 | 5.4 ± 2.8 | 5.9 ± 2.9 |
| Patients at target dose of β-blocker | 76 (27%) | 87 (31%) | 163 (29%) | 1488 (26%) |
| Patients at ≥50% target dose of β-blocker | 159 (57%) | 154 (55%) | 313 (56%) | 3181 (56%) |
Data are numbers of patients (%) or means ± SD.